Related Experiment Video
Updated: Jun 24, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Small molecular inhibitors: Therapeutic strategies for pancreatic cancer
Yuvasri Golivi1, Seema Kumari2, Batoul Farran3
1Department of Bioscience and Biotechnology, Banasthali University, Banasthali, RJ 304 022, India.
Abstract:
Pancreatic cancer (PC), a disease with high heterogeneity and a dense stromal microenvironment, presents significant challenges and a bleak prognosis. Recent breakthroughs have illuminated the crucial interplay among RAS, epidermal growth factor receptor (EGFR), and hedgehog pathways in PC progression. Small molecular inhibitors have emerged as a potential solution with their advantages of oral administration and the ability to target intracellular and extracellular sites effectively. However, despite the US FDA approving over 100 small-molecule targeted antitumor drugs, challenges such as low response rates and drug resistance persist. This review delves into the possibility of using small molecules to treat persistent or spreading PC, highlighting the challenges and the urgent need for a diverse selection of inhibitors to develop more effective treatment strategies.
Insights
Small molecule inhibitors show promise for pancreatic cancer (PC) treatment, targeting key pathways like RAS and EGFR. However, challenges in response rates and drug resistance necessitate developing diverse inhibitors for better outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Pancreatic cancer (PC) is highly heterogeneous with a dense stroma, leading to poor prognosis.
- The interplay of RAS, epidermal growth factor receptor (EGFR), and hedgehog pathways is critical in PC progression.
- Small molecular inhibitors offer targeted treatment advantages but face challenges like low response rates and resistance.
Purpose of the Study:
- To review the potential of small molecules for treating persistent or spreading pancreatic cancer.
- To highlight the challenges associated with current small molecule therapies.
- To emphasize the need for diverse inhibitor development for improved pancreatic cancer treatment strategies.
Main Methods:
- Literature review of recent breakthroughs in pancreatic cancer research.
- Analysis of the role of RAS, EGFR, and hedgehog pathways in PC.
- Evaluation of small molecular inhibitors as therapeutic agents.
Main Results:
- Small molecules can target intracellular and extracellular sites effectively.
- Over 100 small-molecule targeted antitumor drugs are FDA-approved.
- Persistent challenges include low response rates and drug resistance.
Conclusions:
- Small molecules represent a promising avenue for pancreatic cancer therapy.
- Addressing challenges like drug resistance is crucial for treatment efficacy.
- Developing a diverse range of inhibitors is essential for advancing pancreatic cancer treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:15Drugs that Stabilize Microtubules
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...